The Food and Drug Administration (FDA or Agency) is withdrawing approval of new drug application (NDA) 020932 for ROXICODONE (oxycodone hydrochloride (HCl)) Sustained-Release Tablets, 10 milligrams (mg) and 30 mg, held by Roxane Laboratories, Inc. (Roxane). Roxane requested withdrawal of this application and waived its opportunity for a hearing.
Document
Roxane Laboratories, Inc.; Withdrawal of Approval of a New Drug Application for ROXICODONE (Oxycodone Hydrochloride) Sustained-Release Tablets, 10 Milligrams and 30 Milligrams
The Food and Drug Administration (FDA or Agency) is withdrawing approval of new drug application (NDA) 020932 for ROXICODONE (oxycodone hydrochloride (HCl)) Sustained-Release Ta...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
82 FR 56606
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Roxane Laboratories, Inc.; Withdrawal of Approval of a New Drug Application for ROXICODONE (Oxycodone Hydrochloride) Sustained-Release Tablets, 10 Milligrams and 30 Milligrams,” thefederalregister.org (November 29, 2017), https://thefederalregister.org/documents/2017-25771/roxane-laboratories-inc-withdrawal-of-approval-of-a-new-drug-application-for-roxicodone-oxycodone-hydrochloride-sustaine.